BPC-157: What the Research Says About the “Body Protection Compound” Peptide

A research-focused overview of BPC-157 (CAS 137525-51-0): its molecular profile, what preclinical studies have examined, and how it is handled in the lab. For research use only.

BPC-157 is one of the most-studied peptides in the research community — and one of the most misunderstood. This guide summarizes what laboratory research has actually examined about BPC-157, its molecular profile, and how it is handled in a research setting. It is written for researchers and is not medical guidance.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids (CAS 137525-51-0; molecular formula C62H98N16O22; molar mass ≈ 1419.5 g/mol). Its amino-acid sequence is derived from a partial sequence of a protein called Body Protection Compound (BPC), originally identified in human gastric juice. A defining characteristic noted across the literature is its stability — it remains intact in aqueous solution and gastric environments where many peptides degrade, which is part of why it became a frequent subject of preclinical investigation.

Research-use note: BPC-157 is a research chemical. It is not an approved drug or supplement, and the findings below come exclusively from cell-culture and animal-model studies. Nothing here describes or implies human use.

What researchers have studied

The published BPC-157 literature is overwhelmingly preclinical — in-vitro (cell culture) and in-vivo rodent models. The most-cited areas of investigation include:

  • Soft-tissue and tendon research. Studies such as Chang et al. (Journal of Applied Physiology, 2011) examined BPC-157’s effect on tendon-derived fibroblast outgrowth, survival, and migration in cultured cells.
  • Gastrointestinal-tract research. The earliest and largest body of work — reviewed by Sikiric and colleagues (Current Pharmaceutical Design, 2011) — studied BPC-157 in models of gastric and intestinal mucosal injury.
  • Angiogenesis research. Work by Seiwerth and colleagues investigated BPC-157’s relationship to blood-vessel formation during muscle and tendon healing in animal models.
  • Musculoskeletal soft-tissue research. A 2019 review (Gwyer, Wragg & Wilson, Cell and Tissue Research) consolidated animal-model findings on muscle, ligament, and connective-tissue healing.

In each case, the literature describes research findings in laboratory models — not validated outcomes in humans.

Mechanisms under investigation

Researchers studying BPC-157 have proposed several mechanisms to explain the effects observed in animal models, including modulation of growth-factor and nitric-oxide (NO) pathways, interaction with the VEGFR2 receptor in angiogenesis studies, and influence on collagen organization during tissue-repair models. These remain active areas of investigation, not settled conclusions.

Handling and reconstitution in the laboratory

BPC-157 is typically supplied as a lyophilized (freeze-dried) powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (These are general lab-handling notes, not usage instructions.)

Researchers often pair it with bacteriostatic water as the reconstitution diluent.

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice or as describing safe or effective human use.

Explore BPC-157 and related research peptides

References

  1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PubMed
  2. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PubMed
  3. Seiwerth S, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2010. PubMed
  4. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PubMed

Related comparison: BPC-157 vs TB-500 — how the research peptides compare.

2 Comments

Comments are closed.